Pluristem Therapeutics Inc (PSTI)

1.50
NASDAQ : Health Care
Prev Close 1.51
Day Low/High 1.48 / 1.54
52 Wk Low/High 0.71 / 1.85
Avg Volume 108.60K
Exchange NASDAQ
Shares Outstanding 81.02M
Market Cap 122.34M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Pluristem CEO Zami Aberman Re-Elected To Alliance For Regenerative Medicine's Board Of Directors

Pluristem CEO Zami Aberman Re-Elected To Alliance For Regenerative Medicine's Board Of Directors

ARM is the Preeminent Global Advocate for the Advancement of Regenerative Medicine

Pluristem Participates In Radiation Injury Treatment Network Conference Co-sponsored By National Institutes Of Health's NIAID

Pluristem Participates In Radiation Injury Treatment Network Conference Co-sponsored By National Institutes Of Health's NIAID

Pluristem's PLX-R18 is being studied by NIAID for Acute Radiation Syndrome (ARS), and following pharmacodynamics, safety and efficacy trials, the company plans to initiate a pivotal study to gain approval for ARS via the FDA Animal Rule.

Pluristem Continues To Strengthen Its Position In Japan - Granted Two Key Cell Therapy Patents

Pluristem Continues To Strengthen Its Position In Japan - Granted Two Key Cell Therapy Patents

IP addresses both 3D growth of placental and fat cells and the use of placental cells grown with 3D technology for the treatment of hematopoietic disorders

Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights And Clinical Development Update

Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights And Clinical Development Update

Strong Balance Sheet, Two Active Clinical Development Programs in the U.S. Accelerated Pathways to Commercialization in Japan & Europe

Pluristem Therapeutics (PSTI) Stock Surges on FDA Orphan Drug Designation

Pluristem Therapeutics (PSTI) Stock Surges on FDA Orphan Drug Designation

Pluristem Therapeutics (PSTI) stock is popping in mid-morning trading on Thursday after the FDA granted an orphan drug designation to its preeclampsia treatment.

U.S. Food & Drug Administration Grants Orphan Drug Designation To Pluristem's PLX-PAD Cells For Treatment Of Severe Preeclampsia

U.S. Food & Drug Administration Grants Orphan Drug Designation To Pluristem's PLX-PAD Cells For Treatment Of Severe Preeclampsia

PLX Cells Were Demonstrated to be Safe for Both the Mother and Fetus and Improved Several Parameters of Preeclampsia in Several Animal Studies

Pluristem To Present At Phacilitate Cell & Gene Therapy World Conference In Washington DC On January 25-26, 2016

Pluristem To Present At Phacilitate Cell & Gene Therapy World Conference In Washington DC On January 25-26, 2016

Yaky Yanay to Deliver Two Presentations Regarding Accelerated Clinical Development Pathways in Europe and Japan